Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board

Aug 13, 2018

Commences study to assess novel RORγt inhibitor for the treatment of psoriasis Recruits key opinion leaders to guide clinical development of its RORγt programs. NIJMEGEN, The Netherlands and Encinitas, California, August 13, 2018 – Escalier Biosciences, BV, a...

Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders

Jul 23, 2018

Company to address unmet medical needs in the field of rare metabolic disorders Exclusive IP licensed from Leiden University and Amsterdam UMC Senior industry R&D leader Olivier Morand appointed as Chief Executive Officer and member of the Board of Directors...

VarmX raises €12.5 million to develop modified blood coagulation factor X for treating severe bleeding in patients using anticoagulants

Jul 2, 2018

Funding enables clinical stage trials of lead compound PseudoXa € 7.5 million Series A financing from lead investor BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter Financing supplemented by € 5.0 million innovation credit from the...

Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

May 14, 2018

AMSTERDAM, NETHERLANDS – May 14, 2018 – Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc. Dr. Lambert joined ImmunoGen Inc. in 1987 and...

News overview

Next events

BioFit, 4-5 December 2018

Jul 2, 2018

Daniela Couto will be attending the BioFit conference on 4-5 December 2018 in Lille. You can connect with Daniela via email to set up a meeting. https://www.biofit-event.com/

Event overview